Virological outcomes and metabolic effects after switching from ritonavir-boosted protease inhibitors to a dolutegravir-based regimen in virologically suppressed patients living with HIV
暂无分享,去创建一个
[1] C. Fichtenbaum,et al. Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus , 2021, Open forum infectious diseases.
[2] C. Tremblay,et al. Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data , 2020, Open forum infectious diseases.
[3] M. Siedner,et al. Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase , 2020, Nature Communications.
[4] L. Calza,et al. Factors Associated With Weight Gain in People Treated With Dolutegravir , 2020, Open forum infectious diseases.
[5] R. Martínez-Álvarez,et al. Neuropsychiatric adverse effects of dolutegravir in real-life clinical practice. , 2020, Enfermedades infecciosas y microbiologia clinica.
[6] F. Palella,et al. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV , 2020 .
[8] Mark Payne,et al. Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.
[9] G. McComsey,et al. Weight gain and integrase inhibitors. , 2019, Current opinion in infectious diseases.
[10] H. Stellbrink,et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] A. Vos,et al. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. , 2019, New England Journal of Medicine.
[12] M. Peeters,et al. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. , 2019, The New England journal of medicine.
[13] L. Calza,et al. Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients , 2018, The Journal of antimicrobial chemotherapy.
[14] F. Visseren,et al. The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients , 2018, HIV clinical trials.
[15] H. Stellbrink,et al. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk , 2017, AIDS.
[16] J. Levy,et al. Renal effects of novel antiretroviral drugs , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[17] J. Duggan,et al. Evaluation of Serum Creatinine Changes With Integrase Inhibitor Use in Human Immunodeficiency Virus-1 Infected Adults , 2016, Open forum infectious diseases.
[18] B. Clotet,et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. , 2015, The lancet. HIV.
[19] Clare Brennan,et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study , 2013, The Lancet.
[20] C. Tremblay,et al. Association Between HIV Infection, Antiretroviral Therapy, and Risk of Acute Myocardial Infarction: A Cohort and Nested Case–Control Study Using Québec's Public Health Insurance Database , 2011, Journal of acquired immune deficiency syndromes.
[21] D. Cooper,et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials , 2010, The Lancet.
[22] F. Goebel,et al. Hyperlipidemia under treatment with proteinase inhibitors , 1999, Infection.
[23] J. Aberg,et al. Dyslipidemia in HIV patients. , 2005, Cleveland Clinic journal of medicine.
[24] G. Behrens. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. , 2005, The New England journal of medicine.
[25] S. Grundy,et al. National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .
[26] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.